Skip to main content
SearchLoginLogin or Signup

Reviews of "Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152"

Reviewers: Nathaniel Roy Landau (NYU Langone Medical Center) | πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ β€’ Ran Taube (Ben-Gurion University of the Negev) |πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜β€’ Daniele Focosi (Azienda Ospedaliero Universitaria Pisana) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

Published onAug 23, 2021
Reviews of "Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152"
key-enterThis Pub is a Review of
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
Description

AbstractRecently, multiple SARS-CoV-2 variants have been detected across the globe. The recent emergence of B.1.617 lineage has created serious public health problem in India. The high transmissibility was observed with this lineage which has led to daily increase in the number of SARS-CoV-2 infections. Apparently, the sub-lineage B.1.617.2 has slowly dominated the other variants including B1617.1, B.617.3 and B.1.1.7. With this, World Health Organization has described B.1.617.2 as variant of concern. Besides this, variant of concern B.1.351 has been also reported from India, known to showreducedefficacyfor many approved vaccines. With the increasing threat of the SARS-CoV-2 variants, it is imperative to assess the efficacy of the currently available vaccines against these variants. Here, we have evaluated the neutralization potential of sera collected from COVID-19 recovered cases (n=20) and vaccinees with two doses of BBV152 (n=17) against B.1.351 and B.1.617.2 compared to the prototype B.1 (D614G) variant.The finding of the study demonstrated a reduction in neutralization titers with sera of COVID-19 recovered cases(3.3-fold and 4.6-fold) and BBV152 vaccinees (3. 0 and 2.7 fold) against B.1.351 and B.1.617.2 respectively.Although, there is reduction in neutralization titer, the whole-virion inactivated SARS-CoV-2 vaccine (BBV152) demonstrates protective response against VOC B.1351 and B.1.617.2.

To read the original manuscript, click the link above.

Summary of Reviews: This paper presents reliable findings about the efficacy of BBV152 against VOCs B.1351 and B.1.617.2. Although the reviewers agree on the urgency and relevance of this paper they raised concerns about undisclosed affiliations of the authors and the sample size used in the study.

Reviewer 1 (Nathaniel Roy Landau) | πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ

Reviewer 2 (Ran Taube) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

Reviewer 3 (Daniele Focosi) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

RR:C19 Strength of Evidence Scale Key

πŸ“• ◻️◻️◻️◻️ = Misleading

πŸ“™πŸ“™ ◻️◻️◻️ = Not Informative

πŸ“’πŸ“’πŸ“’ ◻️◻️ = Potentially Informative

πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ = Reliable

πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜ = Strong

To read the reviews, click the links below.


Connections
1 of 3
Comments
0
comment
No comments here
Why not start the discussion?